Key Financial Results (Quarter ended June 30, 2026)

  • Revenue from operations: ₹1,813.68 crore (compared to ₹1,738.35 crore in Q1 FY26 and ₹1,709.51 crore in Q4 FY26)
  • Other income: ₹75.37 crore (compared to ₹72.84 crore in Q1 FY26 and ₹75.59 crore in Q4 FY26)
  • Total Income: ₹1,889.05 crore (compared to ₹1,811.19 crore in Q1 FY26 and ₹1,785.10 crore in Q4 FY26)

Expense Breakdown

  • Cost of materials consumed: ₹150.63 crore
  • Purchases of stock-in-trade: ₹812.06 crore
  • Changes in inventories: (₹31.10) crore
  • Employee benefits expense: ₹175.24 crore
  • Finance costs: ₹5.91 crore
  • Depreciation and amortization: ₹19.75 crore
  • Other expenses: ₹184.35 crore
  • Total Expenses: ₹1,316.84 crore

Profitability Metrics

  • Profit before tax: ₹572.21 crore (compared to ₹493.13 crore in Q1 FY26 and ₹531.23 crore in Q4 FY26)
  • Tax expenses: ₹143.69 crore (comprising current tax of ₹146.87 crore and deferred tax credit of ₹3.18 crore)
  • Profit for the period: ₹428.52 crore (17.1% increase from ₹365.86 crore in Q1 FY26)
  • Other Comprehensive Income: ₹0.04 crore
  • Total Comprehensive Income: ₹428.56 crore

Capital Structure and Per Share Data

  • Paid-up Equity Share Capital: ₹21.25 crore (Face Value of ₹10 per equity share)
  • Earnings per equity share (Basic/Diluted): ₹201.66 (compared to ₹172.17 in Q1 FY26 and ₹185.85 in Q4 FY26)

Comparative Financial Data

Year ended March 31, 2026 (Audited):

  • Revenue from operations: ₹6,929.05 crore
  • Other income: ₹288.14 crore
  • Total Income: ₹7,217.19 crore
  • Total Expenses: ₹5,137.92 crore
  • Profit for the year: ₹1,552.02 crore
  • EPS for the year: ₹730.36

Approval and Review Process

  • Board of Directors meeting held on August 12, 2026, from 3:30 pm to 6:25 pm
  • Results reviewed and recommended by Audit Committee
  • Subjected to limited review by statutory auditors Walker Chandiok & Co LLP
  • Limited Review Report contains no qualifications

Accounting and Regulatory Compliance

  • Prepared in accordance with Indian Accounting Standard 34 (Ind AS 34)
  • Compliance with Regulation 33 of SEBI Listing Regulations
  • Company has only one segment: 'Pharmaceuticals'
  • Figures for previous periods regrouped/reclassified where necessary

Additional Information

  • The figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and published year-to-date figures
  • Limited review conducted in accordance with Standard on Review Engagements (SRE) 2410
  • Financial results submitted to BSE Limited for regulatory compliance